Publications
5813 Results
- Journal / Conference
- AACR 2025 Meeting, poster; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT092
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vaginal Cancers
- Journal / Conference
- Nature Medicine. 2025 Nov;31(11):3668-3674. doi: 10.1038/s41591-025-03875-5. Epub 2025 Aug 14.
- Year
- 2025
- Research Committee(s)
- Melanoma
- PMID
- PMID40813711
- PMC
- PMC12419231
- Study Number(s)
- S1512
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
- Journal / Conference
- ASCO Annual Meeting (May 30-June 3, 2025, Chicago, IL), oral, Abstract # LBA9507
- Year
- 2025
- Research Committee(s)
- Melanoma
- Study Number(s)
- S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013)
- Journal / Conference
- ASCO Annual Meeitng (May 30-June 3, 2025, Chicago), rapid oral, Abstract # 8518
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- S1900E
(S1900E: A Phase II Study of AMG 510 in Patients With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-Map Sub-Study))
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), publication only, Abstract # e17109
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216)
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025)
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Prognostic Value of Circulating Tumor DNA in Advanced Stage Classic Hodgkin Lymphoma Patients Treated on SWOG S1826
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster, Abstract # 2600 Poster Bd # 247
- Year
- 2025
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S2013
Baseline autoimmune diseases and characteristics of solid tumor patients on immune checkpoint inhibitor (ICI) therapy enrolled in a prospective study of immune-related adverse events (irAEs): SWOG S2013 (I-CHECKIT)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # 2619 Poster Bd # 266
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Efficacy and Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), publication only, Abstract # e17111
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1802
Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), rapid oral, Abstract # 11016
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- S2302